Undesirable effects related to oral antineoplastic drugs: Comparison between patients' Internet narratives and a national pharmacovigilance database

Drug Safety

Volumn 37, Issue 8, 2014, Pages 629-637

  Pages, Arnaud ^a   Bondon Guitton, Emmanuelle ^a   Montastruc, Jean Louis ^a   Bagheri, Haleh ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ALKYLATING AGENT; ALTRETAMINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BUSULFAN; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; ESTRAMUSTINE; ETOPOSIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; GEFITINIB; HORMONE ANTAGONIST; HYDROXYUREA; IDARUBICIN; IMATINIB; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; NILOTINIB; PIPOBROMAN; PROCARBAZINE; PROTEIN KINASE INHIBITOR; SORAFENIB; TEGAFUR; TIOGUANINE; UFT; UNINDEXED DRUG;

ADVERSE DRUG REACTION; AMBULATORY CARE; ARTICLE; DRUG SURVEILLANCE PROGRAM; FRANCE; HOSPITALIZATION; HUMAN; INTERNET; MUSCULOSKELETAL DISEASE; PATIENT CARE; PRIORITY JOURNAL; SKIN DISEASE; COMPARATIVE STUDY; FACTUAL DATABASE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SELF REPORT;

ADMINISTRATION, ORAL; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; FRANCE; HUMANS; INTERNET; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; SELF REPORT;

EID: 84906213401     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0203-6     Document Type: Article

References (36)

1. Bartlett YK, Coulson NS. An investigation into the empowerment effects of using online support groups and how this affects health professional/patient communication. Patient Educ Couns. 2011;83:113-9.
2. Armstrong N, Powell J. Patient perspectives on health advice posted on Internet discussion boards: a qualitative study. Health Expect. 2009;12:313-20.
3. Lee C, Gray SW, Lewis N. Internet use leads cancer patients to be active health care consumers. Patient Educ Couns. 2010;81:S63-9.
4. Fox S. The social life of health information. Pew Internet, Pew Research Center. 2011. Available: http://www.pewinternet.org/Reports/2011/Social-Life-of- Health-Info.aspx.
5. Schröder S, Zöllner YF, Schaefer M. Drug related problems with antiparkinsonian agents: consumer Internet reports versus published data. Pharmacoepidemio Drug Saf. 2007;16:1161-6. (Pubitemid 350020071)
6. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand. 2009;120:102-11.
7. Wicks P, Massagli M, Frost J, et al. Sharing health data for better outcomes on PatientsLikeMe. J Med Internet Res. 2010;12:e19.
8. Posts about drugs, side effects, conditions and symptoms: Treato. Available at: http://treato.com/. Accessed 10 January 2013.
9. Chee BW, Berlin R, Schatz B. Predicting adverse drug events from personal health messages. AMIA Annu Symp Proc. 2011;2011:217-26.
10. Schultz P, Stava C, Beck M, et al. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs. 2003;7:663-7.
11. Nagler RH, Gray SW, Romantan A, et al. Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns. 2010;81:S54-62.
12. Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22:256-62.
13. Benton A, Ungar L, Hill S, et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J Biomed Inform. 2011;44:989-96.
14. Bordonaro S, Raiti F, Di Mari A, et al. Active home-based cancer treatment. J Multidiscip Healthc. 2012;5:137-43.
15. Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. 2013;69:1819-26.
16. Haramburu F, Miremont-Salamé G, Bénard A, et al. Incidence of hospital admissions due to adverse drug reactions: the EMIR study. Fundam Clin Pharmacol. 2008;22(Suppl 1):20.
17. Le top 5 des sites de santé français: JDN Web & Tech. Available at: http://www.journaldunet.com/ebusiness/le-net/audience-sites-sante/ . Accessed 5 June 2012.
18. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs: actualization of the method used in France. Therapie. 1985;40:111-8.
19. ATC/DDD Index 2013 (n.d.). Available at: http://www.whocc.no/atc-ddd- index/. Accessed 11 August 2012.
20. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109-17. (Pubitemid 29101275)
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74. (Pubitemid 8054849)
22. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-9.
23. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/. Accessed 29 August 2012.
24. Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation. Therapie. 1995;50:557-62. (Pubitemid 26020732)
25. Buetow S, Henshaw J, Cha R, et al. Distinguishing objective from subjective assessments of the severity of medication-related safety events among people with Parkinson's disease: a qualitative study. J Clin Pharm Ther. 2012;37:436-40.
26. Somers A, Petrovic M, Robays H, et al. Reporting adverse drug reactions on a geriatric ward: a pilot project. Eur J Clin Pharmacol. 2003;58:707-14. (Pubitemid 36363301)
27. Sacilotto K, Bagheri H, Lapeyre-Mestre M, et al. Adverse drug effects notifications by nurses and comparison with cases reported by physicians. Therapie. 1995;50:455-8.
28. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24:386-95.
29. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007;25:3797-9. (Pubitemid 47477251)
30. Fontein DBY, Nortier JWR, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy: results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38:110-7.
31. Hughes S, Cohen D. Can online consumers contribute to drug knowledge? A mixed methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. J Med Internet Res. 2011;13:e53.
32. Hazell L, Cornelius V, Hannaford P, et al. How do patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. Drug Saf. 2013;36:199-206.
33. Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148-56. (Pubitemid 46072099)
34. MBongue TB, Sommet A, Pathak A. "Medicamentation" of society, non-disease and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol. 2005;61:309-13.
35. Aboutaam M. Analysis of patients' narratives posted on social media websites on benfluorex (Mediator®) withdrawal in France. J Clin Pharm Ther. 2014;39:53-5.
36. Jarernsiripornkul N, Krska J, Capps PA, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53:318-25. (Pubitemid 34226975)